Neuroscience Center Research Groups

Research in Neuroscience Center focuses on molecular and cellular neuroscience, developmental neuroscience, cognitive and systems neuroscience, and basic research of the diseases of the nervous system. At the moment the Center hosts 20 research groups.

While animal studies have been invaluable for understanding brain functions, animal models of brain diseases translate poorly to humans. This is largely due to fundamental differences in size, structure, complexity and functional capacity between rodents and humans. Human brain shows also substantial genetic variability and sensitivity to environmental and life style factors. We have taken advantage of human induced pluripotent stem cell (iPSC) technology and generated iPSC lines from various neurological and psychiatric diseases. Differentiation of these patient-specific iPSC lines into neurons, astrocytes and microglia allow us to analyze aberrant gene and protein expression as well function and metabolism in developing human brain well before the disease onset. The interplay between different types of glia and neurons can be analyzed in 3-dimentional cultures and cerebral organoids. Transplantation of these cells into the mouse CNS helps us further define the contribution of different human brain cells to the disease. Our models can be exposed to various environmental risk factors and acute brain insults, such as stroke and trauma. As blood-brain barrier is frequently compromised or its dysfunction otherwise contributes to human brain disease, we have combined endothelial cells, pericytes and astrocytes for modelling this important brain structure. The impact of single mutations and potential therapeutic genes are tested by using CRISPR/Cas9 system and virus-mediated gene transfer. We have found that in addition to neurons, astrocytes show aberrant transcriptomic and protein expression profile and have strong phenotype in several neurological and psychiatric disease, which we have confirmed in humanized chimeric mice generated by early cell transplantation. Importantly, we have observed that human brain diseases frequently share the same cellular dysfunction that takes place in different cell types in a disease-specific manner. Using the iPSC-based platform, we are screening small molecule libraries and developing novel biological and small molecules to facilitate drug discovery. Functional imaging and electrophysiological characterization of diseased human brain cells in organoids and living animals is an important part of our future strategy for better understanding the human brain disease.

Our research I s funded by Academy of Finland. Business Finland, European Union and several Finnish and foreign research foundations.

We are interested in mechanisms of neurodegeneration, neuroprotection and brain repair. We focus on studying Parkinson’s disease, stroke, with the ultimate goal being to develop disease-modifying therapies. Drug therapies for neurodegeneration and stroke are based on alleviating symptoms, and the major challenge we have is to find life quality improving treatments for age-related diseases. Our work is based on neuroinflammation, neurogenesis, neurotrophic factors, protein aggregates, endoplasmic reticulum homeostasis and neurotransmission. We have a passion for excellent level research and by internationally evaluated funding and with excellent level collaborators we can push the frontiers of science. Our mission is to provide the highest quality science-based teaching and training.

Neuronal networks are tuned to optimally represent external and internal milieu through neuronal plasticity during critical periods of juvenile life. The Trophin lab is investigating the role of neurotrophic factors and their receptors in neuronal plasticity and drug responses in developing and adult brain.  We have particularly focused on the role of the neurotrophin BDNF (brain-derived neurotrophic factor) and its receptor TrkB in neuronal plasticity and we have shown that antidepressant drugs and anesthetic agents activate BDNF signaling through TrkB. 

We have further found that antidepressants reactivate developmental-like plasticity in the visual cortex and fear extinction circuitry in the adult brain in rodents. When drug-induced plasticity is combined with training or rehabilitation, maladaptive networks wired by an abnormal early life environment can be beneficially rewired in adulthood, which might explain why a combination of antidepressants with psychotherapy work better than either treatment alone.

We are now focusing on the neuronal and molecular mechanisms underlying drug-induced TrkB signaling and investigating how adult plasticity could promote recovery in a variety of neuronal disorders. The lab has been supported by the European Research Council Advanced investigator award and grants from Sigrid Jusélius Foundation and Academy of Finland

My newly formed research group investigates the causes and mechanisms of increased susceptibility to neuropsychiatric disorders by adverse early-life events. These early-life risk-factors include social stress by parental maltreatment, neglect or abuse but also birth-related complications. They have in common that they activate the stress axis of the body and trigger release of stress hormones during critical periods of brain development. We aim to reveal how this postnatal surge in stress hormones affects the ongoing functional development of the serotonergic and dopaminergic system, whose malfunction has long been implicated in mental illness. Moreover, we study long-range interactions after early-life stress within networks regulating emotional behaviour and reactivity such as medial prefrontal cortex, hippocampus and amygdala. We posit that their altered maturation might underlie increased vulnerability to disease later on in life.

Our research efforts have the goal to contribute further insights into the mechanisms that underlie predisposition to neuropsychiatric disorders. Such knowledge is crucial for the development of new treatment strategies that aim at disease prevention.

Our experimental approach includes in vivo electrophysiological recording techniques in combination with pharmacological manipulations and anatomical studies in rodent models.

Alzheimer’s disease (AD), the most common form of dementia, is quickly becoming the most expensive disease of our times. It was recently estimated that the current annual worldwide expenditure for dementia care (~450 billion €) already equals 1% of global GDP. Currently, only symptomatic treatment options are available for AD. Although recent AD research has focused on how to reverse or delay the cerebral amyloid pathology, amyloid-based therapies have not translated well into humans. Thus, Alzheimer’s disease, particularly its sporadic late-onset form, needs to be approached from various perspectives.

The functionality of all cells depends critically on protein-protein interactions (PPI), particularly on the formation of multi-protein complexes. The traditional methods for studying PPIs rely on steady-state analysis of protein complexes that have been extracted from their native cellular environment. This is a significant shortcoming for functional studies. We use Protein-fragment Complementation Assays (PCA), a novel group of methods that allows studying dynamics of PPIs in live cells, to understand basic molecular mechanisms involved in pathophysiology of neurodegenerative diseases. Currently, our focus is on normal cellular regulation of β-amyloid precursor protein (APP) and microtubule-associated protein Tau, molecules that are involved in amyloid plaque and neurofibrillary pathologies in AD, respectively. Our technology platform allows various types of approaches, including mechanistic studies and screening of novel small-molecule modulators of PPIs.

Using the PCA technology, we have recently discovered a mechanism how GABAA receptor activity regulates Tau phosphorylation. GABAA receptor is a target of many psychoactive drugs, such as benzodiazepines, and we are now working to understand what is the role of Tau in these drug responses. In another project, we have revealed a novel mechanism how neuronal apoptosis is regulated by proprotein convertase PCSK9 and lipoprotein receptors ApoER2 and VLDL receptor. These findings are connected to neuronal cholesterol metabolism, an important player in both AD pathophysiology and neuronal plasticity.

The concept of brain as an immune-privileged organ has been permanently bypassed by recent discoveries, including the characterization of a system of lymphatic vessels present in the meninges. These vessels, together with the anatomical structures and the molecular players regulating the movement of fluids within the Central Nervous System (CNS), constitute the unique CNS lymphatic system.

CNS lymphatic system is pivotal in the control of the homeostasis of the brain. In addition, we have recently contribute to demonstrate its key role in the neuro-immune interaction: however, understanding the basic of CNS-immune system communication and of regulation of the different immune responses in the brain remains an unmet priority.

Aim of Neuro-lymphatic Lab is to decipher the functionality of the CNS lymphatic system with a specific focus on its role in the neuro-immune interaction. This is important in order to determine the role of immunity (particularly T-cells) in the pathophysiology of specific neurological diseases, such as traumatic brain injury (TBI).

Using several approaches to manipulate the CNS lymphatic system (which includes transgenic mouse models, virus mediated gene transfer and pharmacological intervention), we analyze the activation of T-cells, their infiltration in the CNS and their interaction with brain- and meningeal-resident cells. Our strategy is focused on in vivo studies using animal models of TBI, migraine and neuronal hyperexcitability. In this frame, we study mechanisms of macromolecules accumulation and clearance from the brain parenchyma, promoting the activation of the neuro-immune response.

A multimodal approach based on in vivo imaging and electrophysiology, behavioral phenotyping and flow cytometry, in combination with molecular and histological techniques, let us to follow up the development and progression of the pathological processes related to the immune response.

Our research goal is to understand the basic mechanisms of neuro-immune interaction, in order to develop novel therapeutic strategies.

Neuro-lymphatic Lab research is funded by Academy of Finland.

Matias Palva group studies the systems-level neuronal mechanisms of emergent neuronal and behavioral dynamics.

Spontaneous brain activity fluctuates in time scales spanning at least across five orders of magnitude. These fluctuations have also been observed on all studied spatial scales and they are statistically governed by spatio-temporal power-laws.

Such a scale-free organization at a macroscopic level is, however, contrasted by salient scale-specific neuronal activities - neuronal oscillations. Our research addresses the functional significance of scale-free and scale-specific brain dynamics in human sensory perception, cognitive performance, and motor output.

We have developed methods for MEG/EEG source reconstruction, optimized cortical parcellations, and quantification of neuronal/behavioral scaling-laws as well as for the mapping of dynamic neuronal interaction networks from invasive and non-invasive electrophysiological recordings of human brain activity. We are also in the process of translating our data management, analysis, and visualization platform into a more easily shareable python package.

Our three main research lines are 1. Assessing the functional roles of brain criticality and connectivity in human cognition by using MEG/EEG and SEEG based connectomes of neuronal couplings and "dynomes" of spatio-temporal dynamics. We are also performing simulations of brain dynamics and utilize several lines of interventional approaches, from electric and magnetic brain stimulation to cognitive training. 2. Identifying the roles of dysconnectivity and dysdynamics in mental disorders such as depression, anxiety, ADHD and schizophrenia, with the major depressive disorder being our main research focus. 3. Developing neuroplasticity-recruiting cognitive training methods for targeted alterations of cortical connectivity and dynamics.

Satu Palva group investigates the functional relevance of neuronal dynamics and large-scale neuronal interactions in human cognition.

In humans, attention, working memory, and consciousness are fundamental cognitive functions, which are serial, introspectively coherent, and have a limited capacity of a few objects. Neuronal processing underlying these cognitive functions is, however, distributed across the brain and over time. The central goal of our group is to understand how local neuronal oscillations, their large-scale interactions and dynamics are related to fundamental cognitive functions. Current theories posit that slow oscillations from delta (1-4 Hz) to alpha (8-14 Hz) bands are related to attentional, executive and control functions, while faster gamma (30+ Hz) band synchronization is related to bottom-up processing of sensory information. We aim to test this framework at the level of large-scale neuronal interactions. Our central hypothesis is that cross-frequency interactions among slow and fast oscillations allow the integration and coordination of neuronal processing across cortical hierarchy.

Both oscillations and behavior also fluctuate in a scale-free manner over several seconds to minutes. This behavior is indicative of critical neuronal dynamics that is thought to enable flexible reconfiguration of behavioral performance and neuronal processing. Our aim is to obtain evidence for this framework and test whether neuronal scaling laws behavior predict scaling laws in behavioral performance.

Many brain diseases are associated with cognitive deficits. We aim to investigate whether aberrant neuronal dynamics and connectivity predict cognitive deficits in neurodevelopmental diseases such as in ADHD and depression.

Our central approaches are to record neuronal activity from human subjects by magneto- and electroencephalography (M/EEG) and from epileptic patients with intracranial EEG (iEEG). We then use transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (TACS) to test the causal role of identified neuronal activities and interactions in coordinating behavioral performance.

Our group focuses on mechanisms of neuronal development and plasticity. Based on neurite outgrowth assays, we have previously isolated, cloned, and produced as recombinant proteins two ligands of heparan sulfate proteoglycans (HSPGs), HMGB1 (high-mobility group B1; amphoterin) and HB-GAM (heparin-binding growth-associated molecule; pleiotrophin).

In addition to heparin/heparan sulfates, HMGB1 binds to the immunoglobulin superfamily protein RAGE (receptor for advanced glycation end-products), which mediates the neurite outgrowth-promoting signal of HMGB1. In addition to growth cone migration, HMGB1/RAGE regulates migration and proliferation of many cell types during development, tumor spread, and inflammation. Studies using the zebrafish model have recently identified HMGB1 as an essential gene for forebrain development.

AMIGO (amphoterin-induced gene and orf) has been identified as an HMGB1-induced gene in hippocampal neurons using ordered differential display. AMIGO defines a novel gene family with three closely related members (AMIGO, AMIGO 2, and AMIGO 3) that belong to both LRR (leucine-rich repeat) and Ig (immunoglobulin) superfamilies of cell surface proteins.  We have recently identified AMIGO as an auxiliary subunit of the Kv2.1 potassium channel. Furthermore, AMIGO affects the channel activity and thereby excitability of neurons.

HB-GAM regulates migration of neurons in developing brain through binding to the transmembrane proteoglycan syndecan-3 (N-syndecan). Furthermore, syndecan-3 acts as a cell surface receptor for GDNF (glial cell-derived neurotrophic factor)-family neurotrophic factors. In addition to HSPG binding, HB-GAM has similar carbohydrate binding sites in chondroitin sulfate proteoglycans (CSPGs). CSPGs are major inhibitory regulators of plasticity and regeneration in the CNS extracellular matrix but our recent experiments have shown that their role can be reversed from inhibition to activation by HB-GAM in the extracellular space. We are currently developing novel treatment strategies for CNS injuries based on the ability of HB-GAM and similar glycosaminoglycan-binding molecules to induce regenerative growth of neurites.

Chloride homeostasis is an important mechanism involved in a variety of cellular events such as volume regulation, proliferation and migration. In neurons the setting of intracellular chloride concentration is in addition crucial for the changes GABAA mediated transmission that take place during development and trauma. These changes are regulated by the functional expression of the chloride transporters KCC2 and NKCC1. Our group has been particularly interested in the interplay between neurotrophic factors and chloride homeostasis. Because neurotrophic factors are regulated by neuronal activity and can regulate inhibitory synapses, they are key molecules to mediate developmental and adult forms of synaptic plasticity during physiological and pathophysiological conditions. In this regard our group has been successful as we have elucidated part of the mechanisms involved in the interplay between intracellular chloride regulation and neurotrophic factors in developing neurons as well as in clinically important paradigms for epilepsy and CNS injury. Neurodegeneration is a devastating sequel common to many neuropathological conditions. A current view is that the brain reacts to pathological insults by activating developmental like programs for survival, regeneration and replacement of damaged neurons.  For instance, after injury mature central neurons become dependent on BDNF trophic support for survival. The reasons for this dependency are poorly studied.  In resent works we descried a novel mechanism explaining the neuroprotective action of BDNF after trauma: a) we found that the post-traumatic effect of GABAA receptors is set by the down-regulation of the K-Cl cotransporter KCC2 and functional presence of Na-K-Cl cotransporter NKCC1; b) post-traumatic GABA depolarization induces p75NTR up-regulation that promotes death signalling; c) BDNF trophic support counterbalance this death signalling and thus exerts a neuroprotective action. However the intrinsic mechanism causing trauma induced decrease of KCC2, BDNF requirement for neuronal survival and consequent rearrangement of post-traumatic network are not known.  We are currently testing how global this mechanism is in different in vivo trauma models. Our current strategy is to develop tools to investigate in more detail this mechanism with the aim to find novel and refined therapeutically approaches to tackle neurodegeneration.

The major function of K-Cl cotranporter KCC2 is to extrude chloride. Resent results have shown that the developmental up-regulation of KCC2 is important for the formation of dendritic spines and formation of glutamatergic synapses. Intriguingly this is not mediated by its chloride extrusion activity but through the interaction of KCC2 with intracellular proteins.  We have now found a number of new intracellular proteins that mediates the regulatory action of KCC2 on the actin cytoskeleton. Our future aim is the implement these tools to investigate the structural role of KCC2 in dendritic spine plasticity and the interplay between inhibitory and excitatory transmission during development and trauma.

Our final aim is to define the role of the interplay between the proteins regulating chloride homeostasis and neurotrophic factors in neuronal wiring and rewiring in the developing and post-traumatic brain.

Increasing number of mouse models is used in the basic biomedical and preclinical research. At the same time, serious concerns have been expressed regarding the validity and reproducibility of animal studies. Therefore, clear demand exists for further research on mouse behavioural biology in laboratory conditions for improving the translational potential. The central problems are the role of environment and animal itself (sex, genetic background). Environmental interventions can be the most powerful methods for enhancing the disease modelling in animals. On the other hand, better methods and consideration of species-specific and ethological paradigms are the key issues in animal-based research. Finally, reporting of animal studies requires improvement and transparency regarding the above mentioned aspects.

The focus of my research is at studying the effects of different housing and testing conditions, husbandry and experimenters on mouse behaviour. Therefore, we are applying a range of behavioural tests to male and female mice of different inbred strains after combination of various environmental treatments or manipulations (caging – open or individually ventilated, nesting materials, other enrichment items, social and individual housing, handling methods, experimenters etc.).

In contrast to classical behavioural testing, where animals are moved to the novel arenas for a brief moment, novel home cage technologies capture the animal behavior 24/7. It is easy to argue, that these methods will become increasingly more important in comprehensive analysis of disease models, allowing sensitive detection of circadian patterns, progression of disease symptoms or outcome of treatment attempts. In my project, automated behavioural monitoring and testing of socially housed mice (IntelliCage) is applied for better understanding and characterization of social behaviour and cognitive performance. IntelliCage can be viewed as a standard environment where the mice are left undisturbed by experimenter and variety of pre-programmed experiments can be applied. We want to expand the application of IntelliCage by developing and validating additional and new protocols for evaluation of behavioural responses related to social interaction, stress, addiction.

Experiments are carried out at the Mouse Behavioural Phenotyping Facility, in close collaboration with other local research groups using behavioural methods, allowing implementation and testing of findings and protocols in different genetically modified mouse lines.

The overall aim of the project is refinement of the methods used for behavioural assessment of mouse models and simultaneously enhance knowledge related to laboratory animal welfare.

Supported by Jane and Aatos Erkko Foundation, Biocenter Finland

How genes manifest phenotypes and regulate disease progression remains main challenge of biomedical research. While our ability to abolish gene function is rather advanced our capacity to enhance gene function while avoiding ectopic expression is relatively limited. We use CRISPR-Cas9 or CRE/Lox based gene editing to conditionally enhance endogenous gene expression. We can now ask when, where and how endogenous gene should be enhanced to model or treat the given disease and for example study how a gene influences developmental process of interest.  Recently, our laboratory received an ERC Consolidator Grant on generating improved mouse models and treatment venues for Parkinson’s disease. We are currently generating tools which allow conditional increase of various genes/pathways important in PD progression.

Our laboratory uses genetic engineering in mouse models and analysis at the molecular, cellular, tissue, “omics”, behavioral and electrophysiological levels. We are, as a new opening, currently implementing alternative model organisms such as zebrafish model. 

As a spin-off from our genetic experiments we have also recently generated a new mouse model for long-segment Hirschsprung’s disease and a new mouse model for Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Anxiety disorders are the most common mental disorders within the EU and cause considerable disability due to high prevalence (14 %), early onset and chronic nature. The major questions in anxiety disorders are which molecular and cellular events lead to and maintain pathological anxiety, and how this pathology can be normalized. We employ a multidisciplinary approach to understand the genetic and neurobiological basis of normal and pathological anxiety. We are especially interested in how the genetic background affects behavior. To this end, we have preclinical models to investigate both innate and psychosocial stress-induced anxiety. We carry out unbiased genome-wide transcriptomic analyses using RNA and microRNA sequencing to identify biological pathways and gene networks that regulate anxiety. Based on these data, we form specific hypotheses that we test using genetic and pharmacological tools, combined with behavioral analysis, to determine the molecular and cellular basis of anxiety. We have recently shown that brain myelin plasticity is a major cellular response to chronic psychosocial stress (Laine et al. eNeuro 2018), and are now investigating the underlying cellular and molecular mechanisms. For this purpose, we are setting up methods to investigate the transcriptomes of specific brain cell types, such as oligodendrocytes, and transcriptomes of single cells of specific brain nuclei. Importantly, we further study the homologous human genes as candidate genes for human anxiety disorders. The goal of our research is to facilitate development of targeted treatment of anxiety disorders by revealing the underlying biological mechanisms.

 The Laboratory of Neurobiology pursues two main lines of research:

1) Ion-regulatory proteins

The most fundamental mechanisms of neuronal signaling are based on movements of ions across the plasma membrane via channels and ion transporters. We are studying the functions of ion-regulatory proteins (IRPs), such as cation-chloride cotransporters (CCCs) and carbonic anhydrases (CAs), in the control of neuronal development, signaling and disease at the molecular, single-cell and network levels. 

When compared to ion channels, IRPs have received much less attention in neurobiological research, but this biased situation is undergoing a profound change that started about a decade ago (see more at the “Milestones” page). In addition to ion regulation, some IRPs also serve as structural elements in neuronal morphogenesis. Because of their multifunctional characteristics, IRPs are involved in diverse brain functions and disorders. 

2) Birth asphyxia

Mammalian birth is always accompanied by a period of obligatory asphyxia during the transition from placental to lung-based breathing. During complicated birth, the duration of the asphyxia is prolonged, leading to a pathophysiological state which is diagnosed as clinical birth asphyxia. This, in turn, is a main cause of neonatal hypoxic-ischemic encephalopathy. Our laboratory is studying the molecular, cellular and network mechanisms underlying the physiological and pathophysiological responses to birth asphyxia in rodents and in human neonates. Our focus is on neuroendocrine signaling based on arginine vasopressin (AVP), and on monitoring changes in brain pH as well as O2 and CO2 levels in order to develop effective means for post-asphyxia resuscitation.

Formation of neuronal circuits is a dynamic process of rapid and concurrent formation and elimination of synaptic connections. During this early development immature neuronal networks typically display spontaneous, rhythmic activity, which is thought to be instrumental in development of the circuitry. How exactly activity shapes synaptic connectivity during development and the molecular mechanisms underlying these processes are not fully understood. The key questions focus on the cellular and molecular mechanisms that link electrical activity to changes in the structure and function of immature synapses and how these are regulated during development. To shed light on these mechanisms, we focus on the development of glutamatergic circuitry in the limbic system, and in particular, on the role of ionotropic glutamate receptors in this process. We aim to understand how the fast Hebbian and the slow, homeostatic plasticity mechanisms operate in the developing circuitry and how they control the transition from immature to mature type synaptic and circuit function. In addition, we are interested to understand how genetic and /or external disturbance influences developmental fine-tuning of the limbic networks and how aberrant development may affect behavior and vulnerability to neuropsychiatric disorders later on in life. Our experimental approach involves the use of in vitro electrophysiological techniques in combination with pharmacological and local genetic manipulation in various neuronal preparations.

Genetically identical cells frequently assume different fates and phenotypes. This widespread phenomenon plays a fundamental role in processes ranging from adaptation to development to disease. Our research focuses on characterizing how specific protein folding and assembly-states modulate cellular information flow and phenotypic plasticity of organisms during adaptation and aging. For this, we employ evolutionary divergent models yeast and neuronal cells and apply multidisciplinary approaches, including proteomic screens, biochemical reconstitutions, genome editing, live-cell imaging, and microfluidics.

Our research has two main directions. We use the single-celled organism budding yeast to understand the molecular underpinnings of aging -  a nearly-universal feature of life. Particularly, we are characterizing how aging leads to rearrangements in proteins regulating translation, metabolism, and proteostasis, and how these changes contribute to known and novel age-related phenotypes. We are also interested elucidating how cells are able to coordinate the retention of such phenotypes during cell division in order to give rise to rejuvenated progeny.

Neurons are highly adaptive and compartmentalized cells that form interconnected networks responsible for complex information processing tasks. Our neuronal work focuses on understanding how the post-synaptic compartments establish and maintain individualized biochemistries during synaptic strengthening, which is critical for their function in storing information. We use systems biology and advanced imaging tools to identify protein folding and assembly mechanisms that contribute to synaptic strengthening. We are equally interested in elucidating how these induced changes are spatially maintained in the activated synaptic compartments to establish functional units for information storage.

Mitochondrial dysfunction has shown out to be a common cause of human inherited disease, with amazing clinical variability, from neonatal fatal multisystem disorders to diabetes, neurodegeneration, dysfertility or tumorigenesis of adult age. Mitochondrial disorders show a wide variation in individual disease severity and progression. Up to date, only few therapy options are available to a limited number of patients. 

Our research group focuses in clarifying the molecular basis of mitochondrial disorders, with a special emphasis on neurodegeneration. We search for disease genes in human sample materials, characterize disease phenotypes and set up DNA-based diagnosis, create disease models based on identified gene defects and utilize these models to study molecular pathogenesis and to test potential treatments.

The specific focus of our group is the disorders involving mitochondrial DNA (mtDNA) maintenance. A plethora of nuclear-encoded proteins are involved in replication, repair and transcription of mtDNA, as well as its copy number regulation. In particular, we clarify the functions of DNA polymerase gamma, the replicative mtDNA polymerase, and its functional companion Twinkle, the replicative helicase. We and others have shown that both of these proteins are involved in a wide variety of dominantly and recessively inherited neurodegenerative disorders, such as MIRAS (mitochondrial recessive ataxia syndrome), Parkinsonism and childhood/juvenile onset epilepsies.

The ultimate aim of our research group is to generate enough knowledge on the mitochondrial disease mechanisms to be able to create therapy. Due to the variability of mitochondrial disease phenotypes, however, it is unlikely that a single therapy would be beneficial for all kinds of mitochondrial dysfunction.

Our group works in close contact with clinical patient care, through excellent collaboration links to child neurology, neurology and pathology departments of Helsinki University and to hospitals throughout Finland, as well as through our responsibilities in HUSLab mitochondrial disease diagnosis.

See website for Academy of Finland Centre of Excellence FinMIT - Research on Mitochondria, Metabolism and Disease

Interactions between genetic and epigenetic factors guide the brain to form from initially randomly connected set of nerve cells to a delicate neuronal network. Concomitantly, intrinsic and sensory input-driven patterns of synchronous electrical activity form ‘functional templates’, which are then converted into stable yet modifiable synapses. These processes define the opening and closing of critical period windows in the brain. Thus, much of the capabilities and limitations of the brain’s later functions and plasticity are set during these periods. Accordingly, these developmental processes can also predispose the brain to various diseases manifested only later in life. Glutamatergic synapses are highly modifiable structures representing the basic units of information processing in the mammalian brain. In addition to rapidly transmitting excitatory signals from neuron to neuron, these synapses have a remarkable capability for activity-dependent plasticity, a process underlying neuronal development as well as adult learning and memory. To this end, we have identified a kainate-type glutamate receptor (KAR) that regulates presynaptic maturation in developing hippocampal neurons (Lauri et al. 2006). It provides a novel mechanism for activation of ‘silent’ synapses during early development and is thus likely to play a critical role in the formation of functional synaptic connections in the hippocampus. In general, we aim to understand how neuronal activity shapes glutamatergic synaptic connectivity during development and what are the mechanisms underlying these processes. We are particularly interested in how the hippocampal synaptic network is fine-tuned by homeostatic and Hebbian mechanisms during the development, and how are these processes associated with the emergent network properties (e.g. synchronous oscillations) in the brain’s limbic areas.  We use wide range of in vitro and in vivo electrophysiological approaches in combination with molecular biological techniques to explore the functional development of the brain.

We are interested in the molecular mechanisms of inherited neurological and neuromuscular disease. Our approach is to use next-generation sequencing technologies to identify disease-causing mutations in Finnish patients. In particular, we have focused on two axon degeneration diseases, Charcot-Marie-Tooth neuropathy (CMT, axonal type) and hereditary spastic paraplegia (HSP). Both diseases are genetically highly heterogeneous, and we have found that also in Finland most disease mutations are family-specific. For CMT2, two founder mutations that both affect mitochondrial function were also found in our studies. In addition to screening known disease genes, we have identified and characterized novel disease genes, which function for example in protein recycling or mRNA export. To study the molecular mechanisms of the disease mutations, we obtain skin biopsies from patients, and use cellular reprogramming to turn the skin cells into pluripotent stem cells that can be differentiated into patient-specific motor neurons. This allows us to study the effects of the mutation in the cell type, which is affected in the patient, but is normally difficult to access for molecular studies. We investigate the motor neurons using molecular, functional, imaging and omics studies. Our aim is to identify common cellular pathways for axon degeneration that could be treatment targets. In rare cases already now the identification of the genetic cause of disease provides a direct possibility for precision therapy. We aim to increase the possibilities for personalized medicine with knowledge of the disease mechanisms. Furthermore, we are interested to identify biomarkers that can be used to evaluate the effects of future treatment trials.

BABA (BAby Brain Activity) is the first clinical research center in Finland dedicated to studying the brain activity of babies. 

BABA research is based on a long tradition of high quality baby research done at the University of Helsinki and Helsinki Children’s Hospital. We, the researchers at BABA, are interested in the early development of the baby brain, with the specific focus of understanding how brain functions emerge early on in life. This is why we study premature babies, neonates, and older infants at BABA.

Our mission is to learn more about the development of brain functions and the effects of illness and other adversities on the infant brain.

We develop new generation methods and techniques for studying the infant brain that allow us to recognize atypical brain development as early as possible.

Socially we serve as a hub of knowledge and collaboration between hospitals, universities, families, and businesses.